← Eichor
Study identifier: NCT04869436 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis

Condition: Chronic Rhinosinusitis With Nasal Polyps · Olfactory Disorder  ·  Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

PhasePhase 4
Planned participants27
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The study aims to investigate the olfactory TDI score (Threshold, Discrimination, Identification) using the Sniffin' sticks test for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) on dupilumab. Twenty-seven adult patients will be followed up during the treatment with dupilumab on three visits to the Otolaryngology Clinic (Baseline, 3 months and 6 months). The primary endpoint will be the TDI score. Nasal polyp score, Quality of Olfactory Disorders - negative symptoms (QOD-NS symptom scores), SNOT-22 will be secondary endpoints.

This description comes directly from the study's public registry record.

Talk to the study team

Cristian Dihel, MD  ·  +15196466100  ·  cristian.dihel@sjhc.london.on.ca

Always discuss trial participation with your own doctor first.

Locations (1)

St. Joseph's Health CareLondon, Ontario, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04869436